Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;36(3):881-884.
doi: 10.1038/s41375-021-01415-x. Epub 2021 Oct 14.

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Arthur Bobin  1 , Maéva Kyheng  2   3 , Stéphanie Guidez  1 , Cécile Gruchet-Merouze  1 , Valentine Richez  4 , Alain Duhamel  2   3 , Lionel Karlin  5 , Brigitte Kolb  6 , Mourad Tiab  7 , Carla Araujo  8 , Nathalie Meuleman  9 , Jean-Valère Malfuson  10 , Pascal Bourquard  11 , Pascal Lenain  12 , Aurore Perrot  13 , Murielle Roussel  14 , Arnaud Jaccard  14 , Marie-Odile Petillon  15 , Karim Belhadj-Merzoug  16 , Marie-Lorraine Chretien  17 , Jean Fontan  18 , Philippe Rodon  19 , Anna Schmitt  20 , Fritz Offner  21 , Laurent Voillat  22 , Sophie Cereja  23 , Frédérique Kuhnowski  24 , Sophie Rigaudeau  25 , Olivier Decaux  26 , Catherine Humbrecht-Kraut  27 , Jamile Frayfer  28 , Olivier Fitoussi  29 , Damien Roos-Weil  30 , Jean Claude Eisenmann  31 , Véronique Dorvaux  32 , Eric G Voog  33 , Philippe Moreau  34 , Hervé Avet-Loiseau  13 , Cyrille Hulin  35 , Thierry Facon  15 ; Intergroupe Francophone du Myelome Multiple (IFM); Xavier Leleu  36
Affiliations

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Arthur Bobin et al. Leukemia. 2022 Mar.
No abstract available

PubMed Disclaimer

References

    1. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–69. - DOI
    1. Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73. - DOI
    1. Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D’Agostino M, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32:1697–712. - DOI
    1. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–10. - DOI
    1. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281–90. - DOI

Publication types

MeSH terms

LinkOut - more resources